Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Seeking Alpha

25 Jun 2026, 18:32 UTC · 2h ago

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript

What the story claims

1 claim · each scored for market impact

What matters in this story

1
The FDA has approved Tryngolza for the treatment of severe hypertriglyceridemia and the reduction of acute pancreatitis risk. — FDA approval is a primary value-driver for biotech companies, opening a new commercial revenue stream.
+0.80

Which stocks this story touches

How each ticker is affected

IONS+1.00
The company received FDA approval for TRYNGOLZA, a significant regulatory milestone for its product pipeline.

Read original · https://seekingalpha.com/article/4917829-ionis-pharmaceuticals-inc-ions-discusses-fda-approval-of-tryngolza-for-severe

6 related stories

Business Wire
10h ago
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
- biotech
- fda approval
- pharmaceuticals
Read

Ionis Pharmaceuticals, In… — IONS +1.00 | NewsImpactScreener

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript

What matters in this story

How each ticker is affected

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript

What matters in this story

How each ticker is affected

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript

ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?

Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript

What matters in this story

How each ticker is affected

Next reads from the same story arc

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript

What matters in this story

How each ticker is affected

Next reads from the same story arc

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript

ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?

Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?